One phenomenon. Four altitudes.
Molecular mimicry runs through the whole of autoimmune disease — from the person living it to the therapy that may one day correct it. Read it across.
We meet pathogens we never notice.
We are exposed to far more pathogens than we ever register — most leave no symptom at all. But where a pathogen's proteins resemble our own, that silent contact can leave a mark: an immune system that learns to attack both. Molecular mimicry turns invisible exposure into a plausible engine of autoimmune disease.
Invisible exposure
Across a lifetime we encounter countless pathogens without ever knowing it. Symptoms are the exception; contact is constant, and largely unmapped.
Molecular mimicry
Where a pathogen protein mirrors a human one, immune tolerance can break and the body may turn on itself. The phenomenon is established — the open questions are which exposures, and in whom.
The mutations ahead
Pathogens keep changing, and every mutation reshapes that resemblance. Reading our relationship with them — today and as it evolves — is where prediction has to start. This is the line our hypotheses follow.
The same phenomenon, seen from four sides.
Patient, clinician, researcher, pharma — each meets molecular mimicry at a different altitude. One line of inquiry, read across four points of view.
What we are building toward.
Molecular mimicry is the beginning, not the destination. These are the directions we are working toward — and where the right partners come in early.
Mapping the unseen
A systematic map of the pathogen exposures that may drive autoimmunity — a data layer that does not yet exist.
Ahead of the mutation
Anticipating how future pathogen mutations reshape molecular mimicry — and what that means for risk before it ever reaches a clinic.
Mimicry as a target
Turning the phenomenon into therapeutic hypotheses — the earliest, most defensible point in the discovery chain, built with pharma partners.
It all began as a question.
Neural Omega started from original bioinformatics research into molecular mimicry — not a gap in a market. That question is still the company's spine: every product is a different altitude on the same line of inquiry, built on a European foundation designed to pursue it properly.
The beginning of a new medicine.
We do not have every answer. We have the map, and we have started to walk it. If you want to see how, let us talk.
Talk to us at BioSpain →